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Appropriate tyrosine kinase signaling depends
on coordinated sequential coupling of protein-
protein interactions with catalytic activation.
Focal adhesion kinase (FAK) integrates signals
from integrin and growth factor receptors to
regulate cellular responses including cell adhe-
sion, migration, and survival. Here, we describe
crystal structures representing both autoinhi-
bited and active states of FAK. The inactive
structure reveals a mechanism of inhibition in
which the N-terminal FERM domain directly
binds the kinase domain, blocking access to
the catalytic cleft and protecting the FAK acti-
vation loop fromSrc phosphorylation. Addition-
ally, the FERM domain sequesters the Tyr397
autophosphorylation and Src recruitment site,
which lies in the linker connecting the FERM
and kinase domains. The active phosphory-
lated FAK kinase adopts a conformation that
is immune to FERM inhibition. Our biochemical
and structural analysis shows how the archi-
tecture of autoinhibited FAK orchestrates an
activation sequence of FERM domain displace-
ment, linker autophosphorylation, Src recruit-
ment, and full catalytic activation.
INTRODUCTION
Focal adhesions are integrin-mediated points of contact
between the cell surface and the extracellular matrix. Co-
ordinated assembly and disassembly of focal adhesions
as well as intracellular signaling from these sites modulate
cell adhesion, migration, proliferation, differentiation, and
survival in response to cues in the extracellular milieu
(Bershadsky et al., 2003; Ridley et al., 2003). Focal adhe-
sion kinase (FAK, gene name ptk2) is a central node in thesignaling network emanating from focal adhesions (Mitra
et al., 2005; Parsons, 2003). FAK is at once a signaling
switch and a signaling scaffold; engagement of integrins
and growth factor receptors on the cell surface induces
catalytic activation of FAK and also promotes its recruit-
ment and activation of Src kinases and other signaling
proteins. FAK is ubiquitously expressed and is required
for diverse developmental processes including neuronal
pathfinding and epithelial and vascular morphogenesis
(Nikolopoulos and Giancotti, 2005; Schock and Perrimon,
2002). FAK-deficient mouse embryos are not viable due to
a poorly developed vascular system (Ilic et al., 1995,
2003). FAK overexpression in invasive tumors and its
probable role in metastasis have made it a target for the
development of anticancer drugs (Cohen and Guan,
2005a; McLean et al., 2005).
FAK and the closely related proline-rich tyrosine kinase
2 (Pyk2, also known as CAKb) share a domain structure
that includes an N-terminal FERM (band 4.1, ezrin, radixin,
moesin homology) domain, followed by an 40 residue
linker region, a central kinase domain, an 220 residue
proline-rich low-complexity region, and a C-terminal focal
adhesion targeting (FAT) domain (Figure 1A). The FAT do-
main consists of a four-helix bundle (Arold et al., 2002;
Hayashi et al., 2002) and is critical for targeting FAK to
focal adhesions via binding to paxillin, but it is not thought
to play a direct role in catalytic regulation of FAK. The
FERM domain is a three-lobed protein-interaction domain
(Pearson et al., 2000) found in a number of cytoskeletal
proteins (Chishti et al., 1998). In FAK, it has been shown
to bind and inhibit the kinase domain (Cooper et al.,
2003) and may mediate interaction of FAK with the
cytoplasmic regions of activating receptors including b-
integrins (Guan and Shalloway, 1992; Schaller et al.,
1992) and the PDGFR (Sieg et al., 2000), EGFR (Sieg
et al., 2000), EphA2 (Carter et al., 2002; Miao et al.,
2000), and c-Met (Chen and Chen, 2006) growth factor
receptors. The precise mechanisms by which cell-surface
receptors initiate FAK activation are not clear, but integrin
or growth factor activation induces FAK to autophosphor-
ylate on Tyr397 within the linker (Schaller et al., 1994).Cell 129, 1177–1187, June 15, 2007 ª2007 Elsevier Inc. 1177
Figure 1. Structure of Autoinhibited FAK
(A) Domain structure of FAK. Key tyrosine
phosphorylation sites are indicated.
(B) Overall structure of autoinhibited FAK
including the FERM, linker, and kinase regions.
In the autoinhibited state, the FERM domain
(blue ribbon representation) binds the kinase
domain (red), primarily through an interaction
between the FERM F2 lobe and the kinase
C-lobe. A section of the linker that contains
the autophosphorylation site Tyr397 (yellow)
is located between the FERM F1 lobe and the
kinase N-lobe. The FERM domain also blocks
access to the active-site cleft and to the kinase
activation loop (A-loop, green). Disordered
segments are indicated as dashed lines. The
staurosporine analog AFN941 is bound to the
active site of the kinase and is shown in stick
representation.
(C) Sequence alignment of the FERM, linker,
and kinase regions of avian FAK (cFAK1), hu-
man FAK (hFAK1), and human Pyk2 (hPyk2).
cFAK1 shares 94% sequence identity with
hFAK1, and hFAK1 shares 43% with hPyk2.
Secondary structure elements are indicated,
and the sequence is shaded to correspond to
the colors in (B). Residues involved in the
FERM F2 lobe/kinase C-lobe interaction are
indicated by an asterisk, and regulatory tyro-
sines are colored magenta.The phosphorylated Tyr397 site and a nearby ‘‘PxxP’’ mo-
tif recruit and activate Src via binding to its SH2 and SH3
domains, and Src in turn phosphorylates Tyr576 and
Tyr577 in the activation loop of the FAK kinase (Calalb
et al., 1995). The activated FAK/Src complex phosphory-
lates substrates including paxillin (Schaller and Parsons,
1995), and p130Cas (Tachibana et al., 1997) and affects1178 Cell 129, 1177–1187, June 15, 2007 ª2007 Elsevier Inc.reorganization of the actin cytoskeleton via Rho-family
GTPases (Mitra et al., 2005).
Among the major classes of nonreceptor tyrosine
kinases, which are all thought to be regulated by intramo-
lecular domain interactions, a structural level understand-
ing is only available for Src (Sicheri and Kuriyan, 1997; Xu
et al., 1997) and Abl (Nagar et al., 2003) kinases, which
share a related SH3-SH2-Kinase regulatory apparatus
(Harrison, 2003). Other major classes with divergent do-
main architectures, including ZAP-70/Syk (SH2-SH2-
Kinase domains) and Jak-family kinases (FERM-SH2-
Pseudokinase-Kinase domains) in addition to FAK, have
not been previously described. In order to understand
the structural basis for FAK regulation and to elucidate
general principles underlying regulation of nonreceptor
kinases, we determined the structure of a large fragment
of FAK, containing the FERM and kinase domains, in an
autoinhibited state. The structure reveals that the autoinhi-
bited assembly is stabilized through an interaction be-
tween the FERM domain and the kinase C-lobe, and we
show that disruption of this interaction activates the
kinase. Strikingly, a section of the linker region that con-
tains the autophosphorylation site Tyr397 is positioned
far from the active site between the FERM domain and
the kinase N-lobe. We demonstrate that the autoinhibited
assembly indeed prevents autophosphorylation of Tyr397
and also blocks Src phosphorylation of the activation
loop. Our structural and biochemical analysis of the FAK
kinase in an active, Src-phosphorylated state shows that
once the activation loop is phosphorylated, the kinase is
no longer subject to inhibition by the FERM domain.
RESULTS
Overall Structure of Autoinhibited FAK
We crystallized a large fragment of avian FAK containing
the FERM, linker, and kinase domains in an inactive,
nonphosphorylated conformation. The 2.8 A˚ resolution
structure reveals a compact assembly with extensive
interactions among the FERM, kinase, and linker regions
(Figure 1B). In this autoinhibited state, the three-lobed
FERM domain bridges between the N- and C-lobes of
the kinase domain, extending across the active site cleft.
The major contact between the two domains is formed
between the F2 lobe of the FERM domain and the
C-lobe of the kinase domain. A portion of the linker
segment containing the Tyr397 autophosphorylation site
binds to a groove on the F1 lobe of the FERM domain
and also makes a glancing contact with the N-terminal
lobe of the kinase domain. We find the same overall con-
formation in two additional crystal forms of autoinhibited
FAK, confirming that the observed domain organization
is not a happenstance of crystal packing (see Table S1
for crystallographic details).
The FERM domain exhibits the characteristic three-
lobed architecture (lobes F1, F2, and F3, Figure 1B), and
its structure is essentially the same as observed previously
in our studies of the isolated FERM domain (Ceccarelli
et al., 2006) (root-mean-square deviation [rmsd] 1.24 A˚).
The Tyr397 autophosphorylation site and flanking resi-
dues in the linker form an antiparallel b strand interac-
tion with the FERM F1 lobe. Strikingly, this contact
positions the side chain of Tyr397 some 35 A˚ away
from the catalytic cleft of the kinase. The linker then
extends into the kinase N-lobe, where it is in van derWaals contact with the N-terminal end of the C-helix
(aC in Figure 1B). The amino-terminal portion of the
linker—including the Src SH3 docking site—is disor-
dered in the present structure (residues 363–393). In-
terestingly, mutation of Lys38 in the F1 lobe has
been shown to increase phosphorylation of Tyr397
(Cohen and Guan, 2005b). This residue is near (but
does not contact) the linker, suggesting the possibility
that it could destabilize the linker/FERM interaction.
The kinase domain in the autoinhibited structure adopts
a conformation similar to that of the isolated kinase
domain in the unphosphorylated state (Nowakowski
et al., 2002; rmsd 1.49) but with a small difference in
the relative orientation between the N- and C-lobes
(a counterclockwise rotation of the N-lobe of approxi-
mately 12 when viewed from above). The staurosporine
compound AFN941, a broad-spectrum protein kinase
inhibitor that was included to improve crystal quality, is
bound in the active-site cleft in a manner analogous to
that observed in other tyrosine kinases including Jak3
(Boggon et al., 2005) and Lck (Zhu et al., 1999). The kinase
activation loop adopts an inactive conformation in which it
extends toward the FERM domain (near Ser46 in the F1
lobe) and is then unstructured between residues Asp573
and Leu584. Although the Tyr576 and Tyr577 phosphory-
lation sites in the activation loop are not visible, they must
lie in the space between the active-site cleft and the F1
and F2 lobes of the FERM domain.
Why is the autoinhibited structure downregulated, and
how will release of the FERM/kinase interface activate
the kinase? The overall structure of the FERM-linker-
kinase assembly suggests multiple inhibitory mecha-
nisms: (1) the position of the FERM domain sterically
blocks access of the kinase domain to potential sub-
strates; (2) the partially unstructured, inactive conforma-
tion of the activation loop is not expected to support
binding of peptide substrates, and the FERM domain
blocks the catalytically competent conformation of the
unphosphorylated activation loop; (3) autophosphoryla-
tion of Tyr397 is inhibited as this segment of the linker is
incorporated into a b sheet in the FERM domain 35 A˚
from the active site; and (4) Tyr576 and Tyr577 within the
activation loop are ‘‘sequestered’’ by the FERM domain,
preventing their efficient phosphorylation by Src. We con-
firm the relevance of these autoinhibitory mechanisms via
comparisons with the active structure of the FAK kinase
and via functional dissection of the FERM/kinase interface
as described in the following sections.
Structure of the Active FAK Kinase Domain
In order to better understand FAK autoinhibition and acti-
vation, we determined the structure of the isolated kinase
domain in an active conformation with both Tyr576 and
Tyr577 phosphorylated. The structure was determined in
complex with Mg2+ and the nonhydrolyzable ATP analog
AMP-PNP at 2.3 A˚ resolution (see Experimental Proce-
dures and Table S1). In this structure, the activation loop
adopts a conformation very different from that in theCell 129, 1177–1187, June 15, 2007 ª2007 Elsevier Inc. 1179
Figure 2. Structure of the Active Kinase
Domain of FAK
(A) The structure of the FAK kinase domain
phosphorylated by Src is shown in ribbon rep-
resentation (green) with the activation loop in
blue. The side chains of phosphotyrosines
576 and 577 and AMP-PNP, which is bound
to the active site, are shown in stick represen-
tation. A Mg2+ ion at the active site is shown
as a yellow sphere.
(B) Close-up view of the activation loop with the
side chains of pY576, pY577, R569, and R545
and the main chains of A579 and S580 shown
in stick representation. A network of hydrogen
bonds (orange dashed lines) involving the
phosphate group of pY577 stabilizes the con-
formation of the activation loop.
(C) Superposition of active and inactive FAK
kinases. The autoinhibited structure is shown
with the FERM domain as a surface represen-
tation (light blue), and the linker and kinase
domains are shown in a ribbon representation
colored yellow and red, respectively. The struc-
ture of the active kinase domain (green ribbon
and blue activation loop) is superimposed
based on the kinase C-lobes. The side chain
of pY576 and the main chain carbonyl of
A579 in the active kinase (both residues are
shown in space filling representations) clash
with the FERM domain in the autoinhibited
structure.autoinhibited structure (Figure 2A). The doubly phosphor-
ylated loop exhibits a b-hairpin-like conformation similar
to that seen in other active tyrosine kinases including the
insulin receptor (Hubbard, 1997), Lck (Yamaguchi and
Hendrickson, 1996), and Jak3 (Boggon et al., 2005). The
observed conformation of the activation loop appears to
be stabilized primarily by hydrogen-bond and electro-
static interactions with the phosphate group of pTyr577
(Figure 2B). The side-chain and phosphate group of
pTyr576 extends into solution. Superposition of the
C-lobes of the active FAK kinase on the autoinhibited
structure reveals a similar overall structure for the kinase
domain (rmsd = 1.44 A˚) but a different conformation of
the activation loop past the DFG motif (Figures 2C and
S1). Whereas in the autoinhibited structure residues
567–573 in the activation loop extend toward the FERM
domain and partially occlude the catalytic cleft, the activa-
tion loop in the active kinase allows free access to the
active site.
In many kinases, the C-helix is an integral regulatory
component; it pivots out of the active-site cleft in the
inactive conformation and is restored to the active posi-
tion by activation loop phosphorylation and/or appropriate1180 Cell 129, 1177–1187, June 15, 2007 ª2007 Elsevier Inc.protein-protein interactions (Huse and Kuriyan, 2002). In
FAK, comparison of the active and autoinhibited kinases
shows that the position of the C-helix (relative to the rest
of the N-lobe) does not change upon activation; it is in
a position typical of active kinases in both states (Fig-
ure 2C). Thus ‘‘C-helix displacement’’ is not an element
of FAK regulation. Additionally, a disulfide bond that was
observed in the previously reported structure of the un-
phosphorylated kinase domain (Nowakowski et al.,
2002) is not present in any of our structures, active or
inactive, and is therefore unlikely to play a role in FAK
regulation.
Superposition of the active kinase domain on the inac-
tive structure also shows that pTyr576 and Ala579 in the
phosphorylated activation loop collide with the FERM do-
main in the autoinhibited structure, suggesting that an ac-
tive conformation of the activation loop and FERM domain
inhibition would be mutually exclusive (Figure 2C).
Phosphorylation of the Activation Loop Overrides
FERM Domain Inhibition
In order to dissect the interrelated roles of FERM domain
engagement and activation loop conformation, we
cellular context.compared the in vitro catalytic activity of the crystallized
FERM+kinase construct with that of the isolated kinase
domain. Both proteins were prepared in defined, homoge-
neous phosphorylation states in which Tyr576 and Tyr577
in the activation loop were either both unphosphorylated
or both phosphorylated. This experiment was performed
using a Y397F mutant of the FERM+kinase protein to
preclude any confounding effects due to Tyr397 phos-
phorylation. We find that in the absence of activation
loop phosphorylation, the FERM-containing protein is
approximately 5-fold less active than the isolated kinase
(Figure 3). Strikingly, phosphorylation of the activation
loop by Src increases the activity of the FERM+kinase
proteinmore than 20-fold, activating it to a level equivalent
to that of the isolated kinase domain in the phosphorylated
state. Considering this result and the steric incompatibility
of the phosphorylated activation loop and FERM engage-
ment, we conclude that once the activation loop is
phosphorylated, the FERM domain is no longer able to
downregulate FAK activity in vitro. These findings suggest
that in a cellular context, dephosphorylation of the FAK
activation loop will be a necessary step in restoration of
the autoinhibited state.
The Conserved FERM/Kinase Interface Inhibits FAK
There are two points of contact between the FERM and
kinase domains: a glancing, indirect contact that connects
the FERM F1 lobe via the linker segment to the kinase
N-lobe and a more extensive and direct contact between
the F2 lobe and the kinase C-lobe (Figures 1B, 4A, and
4B). The latter buries a surface area of 649 A˚2 and appears
to be the major source of stabilization for the autoinhibited
assembly (Figure 4A). It is also highly conserved across
species in both FAK and the related Pyk2 families (Figures
1C and 4C).
In order to test the importance of these interactions in
FAK regulation, we introduced mutations at the FERM/
kinase interface and tested their effects on FAK activation
and phosphorylation in vitro and in vivo. To disrupt the
contact with the kinase C-lobe, we mutated either the
FERM F2 lobe (Y180A, M183A double mutant) or
Phe596 in the kinase domain (F596D). In the N-lobe inter-
face, we mutated Ser463 in the kinase C-helix (S463Y;
Figure 4B). We find that both the Y180A, M183A, and
F596D mutants have dramatically increased kinase activ-
ity as compared with the wild-type (WT) protein in vitro
(Figure 4D). Additionally, both proteins have a larger
hydrodynamic radius than the WT protein as measured
by size-exclusion chromatography (Figure 4E). Not unex-
pectedly, mutation of Ser463 in the very modest N-lobe
interface only slightly increased FAK activity (Figure 4D),
and this mutant eluted from the sizing column at a volume
very close to that of the WT protein (Figure 4E). We expect
that the larger hydrodynamic radius of the activated
mutants reflects an ‘‘open’’ conformation in which the
FERM domain is released entirely from the kinase domain,
but we have not ruled out the possibility of dimerization oran alternative mode of FERM domain interaction that
results in a larger hydrodynamic radius.
Mutations in the FERM/kinase interface also activate
full-length FAK both in vitro and in vivo. We studied the
same mutants described above and also an additional
activated FERM domain variant (a V196D, L197D double
mutant). We transiently expressed WT or mutant FAK in
293 cells and found that activating mutations led to
increased levels of autophosphorylation on Tyr397 and
Src phosphorylation on Tyr576, -577, -861, and -925
(Figure 5A). We further assayed phosphorylation of
recombinant paxillin by immunoprecipitated FAK pro-
teins. All of the activated mutants readily phosphorylated
paxillin, whereas the WT and S463Y proteins did so far
less efficiently (Figure 5B). Importantly, the activated
mutants induced higher levels of cellular tyrosine phos-
phorylation and also more efficiently phosphorylated
coexpressed paxillin in 293 cells (Figures 5C and 5D).
Finally, the activating mutants also abrogated the usual
adhesion-dependence of FAK activation (Figures 5E and
S2A). We confirmed that FAK and paxillin phosphorylation
was indeed mediated by FAK and not Src by employing
a FAK kinase dead mutant or a Src-specific kinase inhib-
itor (Figures S2B and S2C). Further, we confirmed that
disruption of the FERM/kinase interface does not affect
FAK localization to focal adhesions (Figure S3). These
results demonstrate that the regulatory interactions we
describe here are relevant to the full-length kinase in a
Figure 3. Phosphorylation of the Activation Loop Overrides
FERM Domain Inhibition
The in vitro kinase activity of the FAK kinase (FAK411-686) and single-
chain FERM+kinase (FAK31-686) proteins is plotted for proteins that
are unphosphorylated (n) or phosphorylated on Y576 and Y577 (y).
Phosphorylated proteins were obtained by treatment with Src and
subsequent repurification of phosphorylated FAK proteins. Note the
reduced activity of the FERM+kinase protein compared to that of the
isolated kinase domain prior to Src phosphorylation. Phosphorylation
of the FERM+kinase protein by Src on Tyr576 and Tyr577 (shown for
Y397F mutant; see text) yields an activity equal to that of the isolated
kinase domain in the phosphorylated state. Error bars represent stan-
dard deviation (SD) from four experiments.Cell 129, 1177–1187, June 15, 2007 ª2007 Elsevier Inc. 1181
Figure 4. The FERM/Kinase Interface
Inhibits FAK
(A) Detailed view of the interaction between the
FERM F2 lobe and the kinase C-lobe. Side
chains that participate in the interaction are
shown in stick form and are labeled. At the cen-
ter of the interface F596 on the kinase domain
inserts into a hydrophobic pocket on the
FERM domain formed by Y180, M183, V196,
and L197. The periphery of the interaction is
predominantly polar. Interdomain hydrogen
bonds are shown as yellow dashed lines.
(B) Detailed view of the linker region, which
forms a b sheet interaction with the FERM F1
lobe and contacts the kinase N-lobe. Side
chains of the autophosphorylation site Y397
and residues at the linker/kinase contact point
are shown.
(C) Surface representation of separated FERM
(right), linker (center), and kinase (left) domains
colored according to sequence conservation.
Viewing angles are indicated relative to
Figure 1B. Conservation is indicated with
a color scale from red (most highly conserved)
to green (most variable). Note that the interact-
ing surfaces of the FERM F2 lobe and kinase
domain are highly conserved. Additionally,
a patch of residues at the bottom of the F2
lobe (a potential binding site for a competitive
activator; see text) and Trp266 and surrounding
residues on the FERM F3 lobe are also highly
conserved. Interestingly, Trp266 and adjacent
residues on the FERM domain form the same
2-fold symmetric ‘‘dimer’’ interaction in every
crystal structure containing the FERM domain,
even though these FAK proteins appear to be
monomeric in solution. The analysis was per-
formed with ClustalW (Chenna et al., 2003)
and ConSurf (Glaser et al., 2003) servers, and
the figure was generated with Pymol (DeLano,
2002).
(D) In vitro kinase activity of purified WT and
mutant FERM+kinase proteins are plotted as negative slopes of NADH depletion (see methods). Disruption of the FERM F2 lobe/kinase C-lobe
interface (Y180A, M183A, and F596D mutations) activates the autoinhibited form of FAK. Error bars represent SD from four experiments.
(E) Size-exclusion chromatography of purified WT and mutant single-chain FERM+kinase proteins. Stokes radii were calculated by comparison with
standards (Catalase, Aldolase, BSA, Ovalbumin, Chymotrypsinogen, and Ribonuclease; Siegel and Monty, 1966). Mutations that activate FAK result
in a larger stokes radius, indicating an ‘‘open’’ conformation, compared to the ‘‘closed’’ autoinhibited form.Activating Phosphorylation Sites Are Sequestered
Because the Tyr397 autophosphorylation site is incorpo-
rated into a b sheet of the FERM domain and because
the FERM domain apparently blocks access of Src to
the activation loop, we sought to test whether protection
of these sites from phosphorylation indeed contributes
to FAK inhibition. We compared Tyr397 autophosphoryla-
tion of the autoinhibited, WT protein with that of the
mutants that release the FERM/kinase interface
(Figure 6A). In the activated mutants we expect an
increase in autophosphorylation for two reasons: loss of
repression of the kinase domain and also exposure of
the Tyr397 phosphorylation site. To distinguish between
these effects, we included a substrate in which the
Tyr397 site is fully exposed as an internal control (F–L,1182 Cell 129, 1177–1187, June 15, 2007 ª2007 Elsevier Inc.which contains the FERM and linker regions of FAK, resi-
dues 31–405). We find that both the F596D and Y180A,
M183A FERM+kinase mutants autophosphorylate their
Tyr397 site as efficiently as they phosphorylate the
exposed Y397 in the control substrate (Figure 6A). In
contrast, in the inhibited FERM+kinase proteins (WT and
S463Y) autophosphorylation was markedly less efficient
than Tyr397 phosphorylation of the control substrate.
Hence, we conclude that Tyr397, as positioned in
autoinhibited FAK, is indeed protected from autophos-
phorylation, and that this protection is lost when the
FERM domain is released from the kinase. It remains
unclear whether physiologically relevant autophosphory-
lation of Tyr397 occurs in cis, in trans, or by both
mechanisms, but kinase-inactive FAK can clearly be
Figure 5. Analysis of WT andMutant FAK
in HEK293 Cells
Mutations were introduced into full-length FAK
to disrupt the interaction of the FERM F2 lobe
with the kinase C-lobe (Y180A, M183A and
V196D, and L197D on the FERM domain and
F596D on the kinase domain) or to disrupt the
contact of the linker with the kinase N-lobe
(S463Y).
(A) Full-length WT or mutant FAK proteins were
transiently expressed in HEK293 cells, and cell
lysates were analyzed by western blotting with
the indicated phosphospecific antibodies or
with the 4.47 anti-FAK antibody.
(B) In vitro kinase assay for paxillin phosphory-
lation. WT and mutant full-length FAK proteins
were immunoprecipitated fromHEK293 lysates
using BC4. The immune complex was incu-
bated in a kinase assay utilizing recombinant
GST-paxillin-N-C3 as an exogenous substrate
(Lyons et al., 2001). Phosphorylation of paxillin
was detected using the phosphospecific
antibodies pY31 and pY118, as well as the
4G10 phosphotyrosine antibody. Equal amounts of substrate were verified by blotting for paxillin using a polyclonal antiserum. Equal recovery of
FAK proteins in the immune complex was verified by blotting for FAK.
(C) HEK293 cells transiently expressing FAK proteins were lysed and analyzed for cellular phosphotyrosine by western blotting cell lysates with 4G10.
(D) Paxillin and FAK were transiently coexpressed in HEK293 cells, and paxillin phosphorylation was analyzed by western blotting lysates using the
pY31 antibody (upper panel). Lysates were blotted for paxillin using a monoclonal antibody as a loading control (middle panel) and for FAK to verify
comparable expression of the WT and mutant FAK proteins (bottom panel).
(E) WT or mutant full-length FAK was transiently expressed in FAK null cells. Adherent cells (Ad), or cells incubated in suspension at 37C for 1 hr (sus)
were lysed. FAK was immunoprecipitated using BC4 and the immune complexes analyzed by western blotting for phosphotyrosine using 4G10 (top
panel). Equal amounts of FAK in the immune complexes were verified by blotting for FAK (bottom panel).transphosphorylated on Tyr397 in vivo (Leu and Maa,
2002; Toutant et al., 2002; Sieg et al., 2000). In vitro, we
find that Tyr397 phosphorylation can occur both in cis
and trans (Figure S4). In any case, our structural and
biochemical results show that incorporation of the
Tyr397 site as a b strand in the FERM F1 lobe does indeed
protect it from autophosphorylation, whether it occurs in
cis or trans.
We also compared the ability of Src to phosphorylate
the activation loop of WT versus mutant FAK. Both the
F596D and Y180A, M183A proteins were more rapidly
phosphorylated on Tyr576 and Tyr577 by Src in vitro (Fig-
ures 6B and 6C), although the in vitro effect is not as
striking as that observed in 293 cells (Figure 5A). The
increased levels of FAK phosphorylation on Tyr576, -577,
-861, and -925 observed in 293 cells (Figure 5A) is
likely due both to exposure of the activation loop in
the active state (as demonstrated above in vitro) and
to enhanced recruitment and activation of Src kinases
to the Tyr397 autophosphorylation site (Figure S2D).
DISCUSSION
To a remarkable extent, the logic of FAK signaling is
encoded in the structure of the autoinhibited enzyme.
The architecture of autoinhibited FAK appears to have
evolved to enforce orderly, sequential activation in re-
sponse to receptor engagement (Figure 7). In the autoinhi-
bited state, the kinase is locked in an inactive conforma-tion, and the activating phosphorylation sites in both the
linker and the activation loop are sequestered. Release
of the FERM domain would appear to be required to allow
autophosphorylation of Tyr397 and subsequent steps in
activation. In analogy with Src-family kinases, which are
activated by displacement of their SH3 and/or SH2 do-
mains (Moarefi et al., 1997), we propose that FERM do-
main displacement is a key initial step in FAK activation.
In this regard, a conserved basic patch on the F2 lobe of
the FERM domain that is immediately adjacent to the
site of contact with the kinase domain has been shown
to be important for FAK activation (Chen and Chen,
2006; Dunty et al., 2004). It is tempting to speculate that
this site could represent an initial site of docking for an
activating protein, which might then directly disrupt the
FERM/kinase interface to activate FAK. Precisely how
integrin or growth factor engagement couples to FAK
activation, andwhether the coupling is direct (for example,
via integrin cytoplasmic tails) or involves additional pro-
teins, will require further investigation. Irrespective of the
mechanism of its displacement, once the FERM domain
is released, Tyr397 is rapidly autophosphorylated, and
the activation loop is exposed for Src phosphorylation,
indicative of a cooperative ‘‘disassembly’’ of interactions
among the FERM, linker, and kinase regions. Subsequent
Src recruitment to the Tyr397 site and phosphorylation of
the activation loop yield the fully active FAK enzyme.
Comparison of FAK and Src reveals marked differences
in their autoinhibitory mechanisms but also fundamentalCell 129, 1177–1187, June 15, 2007 ª2007 Elsevier Inc. 1183
similarities. In Src kinases, the SH3 and SH2 domains
assemble on the ‘‘back’’ of the kinase domain, opposite
the catalytic cleft, and inactivate the kinase domain
indirectly by stabilizing an inactive conformation in which
Figure 6. Tyrosine Phosphorylation Sites Are Protected in
Autoinhibited FAK
(A) Time course of autophosphorylation at Tyr397 was carried out for
WT and mutant purified single-chain FERM+kinase proteins (upper
bands, labeled F-L-K for FERM-Linker-Kinase). FERM+linker protein
(Y180A, M183A mutant), which has Y397 exposed, was included in
the reactions as a control substrate (lower bands, labeled F-L for
FERM-Linker). Tyr397 phosphorylation was monitored by western
blotting using a specific anti-pY397 antibody (left panels). As loading
controls, equivalent gels were stained by Coomassie (right panels).
Note that autoinhibited FERM+kinase proteins (WT and S463Ymutant)
autophosphorylate on Y397 much less efficiently than they phosphor-
ylate Y397 of the control substrate but that this discrimination is lost on
the open mutants (Y180A, M183A and F596D), which autophosphory-
late as rapidly as they phosphorylate the control substrate. Also, note
the overall increase in phosphorylation in the openmutants, consistent
with their increased catalytic activity (as shown in Figure 4C).
(B and C) Time course of Src phosphorylation of WT and mutant
FERM+kinase on Tyr576 and Tyr577. Phosphorylation was monitored
by western blotting using specific antibodies against pY576 (B, left
panels) or pY577 (C, left panels), and equivalent gels were Coomassie
stained as loading controls (right panels). Note that Src phosphoryla-
tion of the activation loop tyrosines is diminished in the intact, autoin-
hibited protein.1184 Cell 129, 1177–1187, June 15, 2007 ª2007 Elsevier Inc.the C-helix is displaced from the active site (see Boggon
and Eck, 2004; Sicheri and Kuriyan, 1997 for review). In
contrast, the FAK FERM domain directly blocks the cata-
lytic cleft, and the overall conformation of the FAK kinase
is remarkably similar in the autoinhibited and active
conformations. Although Src is fully activated by auto-
phosphorylation, FAK requires partnership with Src to
achieve full catalytic activity. Despite their very different
domain architectures and mechanisms of kinase inhibi-
tion, Src and FAK do share similar features that are funda-
mental to their function. In both, linker segments that
connect the regulatory and kinase domains are used to
stabilize the autoinhibited assembly, in addition to direct
contacts between the regulatory and catalytic domains.
Furthermore, in both kinases the activating phosphoryla-
tion sites are sequestered in the inactive conformations,
and appropriate interactions with the regulatory domains
are expected to disassemble the autoinhibitory interac-
tions to expose these sites for phosphorylation. These
similarities in Src and FAK may represent underlying
‘‘design principles’’ in tyrosine kinase signal transduction,
as it is likely that they evolved independently in both
kinases.
EXPERIMENTAL PROCEDURES
Protein Expression and Crystallization
Avian FAK containing the FERM and kinase domains (WT and mutant
FAK31-686) or only the kinase domain (FAK411–686) were expressed
in insect Hifive cells (Invitrogen) using the baculovirus expression sys-
tem. The FERM domain was expressed and purified as described in
Ceccarelli et al. (2006). FERM+kinase proteins (expressed as GST
fusions) were initially purified by affinity purification on glutathione
Sepharose beads (GE Healthcare). After TEV cleavage (to remove
GST), proteins were further purified by anion-exchange (MonoQ, GE
Healthcare) and size-exclusion (Superdex200, GE Healthcare) chro-
matography. Purified autoinhibited FERM+kinase was concentrated
to approximately 10 mg/ml in 20 mM Tris pH 8.0, 200 mM NaCl, 5%
Glycerol, and 2 mM TCEP for crystallization. Optimal crystallization
was performed in hanging drops by mixing the protein with an equal
volume of 13% PEG10K, 250 mM NaCl, 100 mM Tris pH 8.5, 10 mM
TCEP, and 0.2 volume of a 1 mg/ml aqueous suspension of AFN941
(Novartis). Crystals were flash frozen in liquid nitrogen after briefly
soaking in precipitant solution containing additionally 25% ethylene
glycol (EG) as cryoprotectant. The FAK kinase domain (expressed
with 6xhis-tag) was initially purified onNi Sepharose beads (GEHealth-
care). Subsequently, the his-tag was removed with TEV protease.
Further purification was carried out by cation-exchange (MonoS, GE
Healthcare) and size-exclusion (Superdex200) chromatography. The
purified FAK kinase domain was incubated for 6 hr at RT with human
Src (containing SH3, SH2, and kinase domains and a phosphorylated
Tyr416) at a molar Src:FAK ratio of 1:50. Phosphorylation on Tyr576
and Tyr577 was monitored with specific anti-pTyr antibodies
(Biosource), and unphosphorylated protein was removed by cation-
exchange chromatography (MonoS). Phosphorylated kinase was fur-
ther purified, and buffer was exchanged by size exclusion and concen-
trated to 4mg/ml in 20mMHEPES pH 7.0, 150mMNaCl, 5%Glycerol,
and 2 mM TCEP. Crystallization was performed by preincubating the
protein with 2 mM AMP-PNP and 4 mM MgCl2 for 1 hr at 4
C before
setting up hanging drops with equal volume of 26% PEG4K, 200 mM
LiSO4, 100 mM Tris pH 8.5, and 10 mM TCEP. Crystals were flash
frozen in precipitant containing 18% EG.
Figure 7. Schematic of Autoinhibited
FAK and a Sequential Model of Activation
In the inactive state (left), the FERM domain
blocks the kinase active site and sequesters
the Tyr 397 and activation loop phosphoryla-
tion sites. Although not observed in the present
structure, we indicate the docking of the PxxP
motif in the linker to the F3 lobe of the FERM
domain based on previous work (Ceccarelli
et al., 2006). We propose that FAK activation
will be initiated by displacement of the FERM
domain by competitive binding of an activating
protein (orange star) to the FERMF2 surface. Such interactions have not been structurally characterized, but candidate activating proteins include the
cytoplasmic regions of b-integrins or growth factor receptors EGFR, PDGFR, c-Met, or EphA2. Disassembly of the autoinhibited conformation allows
rapid autophosphorylation of the linker residue Tyr397 and exposes the Src docking sites in the linker (center panel). In a subsequent step, Src is
recruited and activated via SH2 binding to pTyr397 and SH3 binding to the PxxP sequence in the linker region. Localized Src then phosphorylates
the activation loop residues Tyr576 and Tyr577 of FAK (right panel). Phosphorylation of the activation loop yields full catalytic activity and, even in the
event of activator dissociation, will not allow kinase inhibition by the FERM domain. Note that for simplicity we have depicted FAK autophosphory-
lation in cis; it may, however, also occur in trans.Data Collection and Structure Determination
Data were collected at beamline 24-ID (NE-CAT) at the Advanced
Photon Source (Argonne National Laboratory) and beamline X29A at
the National Synchrotron Light Source (Brookhaven National Labora-
tory). Data were processed with HKL2000 (Otwinowski and Minor,
1997) and yielded the following space groups and cell parameters:
C212121, a = 67.5, b = 91.3, c = 250.7 A˚ for FERM+kinase crystals
and P212121, a = 44.3, b = 71.8, c = 86.9 A˚ for active kinase crystals.
Phases were calculated using the molecular replacement program
PHASER (Storoni et al., 2004), using the FAK FERM (2AEH; Ceccarelli
et al., 2006) and/or the kinase domain (1MP8; Nowakowski et al., 2002)
as molecular search probes. Both structures contained one molecule
in the asymmetric unit cell (52.1% solvent, VM = 2.57 A˚
3/Da,
(Matthews, 1968) for the FERM+kinase structure and 44.9% solvent,
VM = 2.23 A˚
3/Da for the active kinase structure). Refinement was
performed using the program Refmac (Murshudov et al., 1997), and
manual rebuilding was carried out with the programs O (Jones et al.,
1991) and Coot (Emsley and Cowtan, 2004). Final R factors obtained
were 21.7/27.4 (Rwork/Rfree) for the FERM+kinase structure and 21.4/
26.3 for the active kinase structure. Due to disorder residues 31–34,
363–393, and 574–583 were not included in the final FERM+kinase
structure. For a complete summary of data collection and refinement
parameters see Table S1.
In Vitro Kinase Assays
Kinase assays were essentially performed as described in LaFevre-
Bernt et al. (1998). In brief, 1 mM kinase was added to a reaction
mixture containing 20 mM HEPES pH 7.0, 150 mM NaCl, 1 mM
TCEP, 10 mM MgCl2, 100 mM phosphoenolpyruvate, 0.28 mM
NADH, 0.08 units/ml pyruvate kinase, 0.1 units/ml lactate dehydroge-
nase, and 100 mM E4Y (as polyGlu-Tyr, 4:1 Glu:Tyr, Sigma), and reac-
tions were initiated by addition of 0.5 mM ATP. NADH depletion (which
is coupled to the rate of the kinase reaction) was monitored by absor-
bance at 340 nm using a Spectra MAX Plus spectrometer (Molecular
Devices). For assaying activation-loop-phosphorylated states of the
FAK kinase or FERM+kinase, proteins were incubated for 6 hr at RT
with human Src (containing SH3, SH2, and kinase domains) at a molar
Src:FAK ratio of 1:50. Phosphorylation on Tyr576 and Tyr577 was
monitored with specific anti-pTyr antibodies (Biosource), and unphos-
phorylated protein and Src were removed by subsequent ion-
exchange and size-exclusion chromatography.
Size-Exclusion Chromatography
75 mg of WT or mutant FERM+kinase proteins were injected onto
a PC3.2/30 Superdex 200 (column volume = 2.4 ml), and eluting
proteins were detected by absorption at 280 nm. Stokes radii werecalculated via elution volumes of Catalase, Aldolase, BSA, Ovalbumin,
Chymotrypsinogen, and Ribonuclease (Siegel and Monty, 1966).
Auto and Src Phosphorylation
FERM+kinase proteins as expressed in insect cells were partially
phosphorylated on Y397. Therefore, proteins were first dephosphory-
lated for 4 hr at RT with CD45 phosphatase at a molar CD45:FAK ratio
of 1:20 molar. Dephosphorylation was monitored by western blotting
using a specific anti-pTyr 397 antibody (Biosource). Autophosphoryla-
tion reactions were performed at RT with 1 mM dephosphorylated
FERM+kinase protein (FAK31-686 WT or mutant) and 1 mM mutant
FERM+linker protein (FAK31-405 Y180A, M183A) in 20 mM Tris pH
8.0, 150 mM NaCl, 5% Glycerol, 1 mM TCEP, 1 mM sodium vanadate,
2 mM ATP, and 4 mM MgCl2. For Src phosphorylation reactions 2 mM
FERM+kinase protein, 0.2 mM human Src (SH3+SH2+kinase), and
otherwise identical conditions as for autophosphorylation reactions
were used. Equal amounts were removed at time points indicated in
Figure 6 and analyzed by western blotting using a specific anti-
pTyr397 antibody for autophosphorylation or anti-pTyr576 and anti-
pTyr577 antibodies for Src phosphorylation reactions (Biosource).
Analysis of FAK in HEK293 Cells
For expression of full-length FAK in cells, mutations were engineered
into pcDNA3.1-FAK constructs. The avian paxillin cDNA was subcl-
oned into pcDNA3-1 for transient expression. HEK293 cells were
maintained in Dulbecco’s modified Eagle’s medium/Ham’s F-12
medium containing 10% fetal bovine serum. Cells were transfected us-
ing Lipofectamine Plus according to the manufacturer’s recommen-
ded protocol (Invitrogen). Cells were lysed 24 hr post transfection
using modified RIPA buffer (Reynolds et al., 1989). Phosphorylation
was examined by western blotting cell lysates using phosphospecific
antibodies (anti-pY925 antibody was obtained from Santa Cruz, and all
others were obtained from Biosource). For immune complex kinase
assays, FAK was immunoprecipitated using the BC4 polyclonal
antiserum, and the immune complex was incubated with 2 mg of
GST-paxillin-N-C3 for 10 min using previously described kinase reac-
tion conditions (Lyons et al., 2001). The reaction was terminated by the
addition of sample buffer and phosphorylation of paxillin examined by
western blotting with phosphospecific antibodies (Biosource) or the
4G10 phosphotyrosine antibody (UBI). FAK was detected by western
blotting using the 4.47 antibody (UBI). A polyclonal antibody (Thomas
et al., 1999) or a commercially available monoclonal antibody (BD
Transduction Labs) was used for paxillin blotting. For detection of
adhesion-dependent FAK phosphorylation WT or mutant full-length
FAK was transiently expressed in FAK null fibroblasts. In some exper-
iments, cells were taken into suspension by trypsinization andCell 129, 1177–1187, June 15, 2007 ª2007 Elsevier Inc. 1185
incubated in suspension at 37C for 1 hr. The cells were collected by
centrifugation and lysed inmodified RIPA buffer. FAKwas immunopre-
cipitated using BC4 and analyzed by western blotting using the 4G10
phosphotyrosine antibody (UBI).
Supplemental Data
Supplemental Data include four figures and one table and can be
found with this article online at http://www.cell.com/cgi/content/full/
129/6/1177/DC1/.
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Accession Numbers
The atomic coordinates of autoinhibited FERM+kinase and the phos-
phorylated kinase domain of FAK have been deposited in the Protein
Data Bank with the accession codes 2J0J and 2J0L, respectively.
Note Added in Proof
In the recently reported structure of autoinhibited ZAP-70 (Deindl et al.,
2007), the tandemSH2 domains bind to the back of the kinase domain,
remote from the active site, and induce a Src-like inactive conforma-
tion of the kinase domain. Though this architecture is distinct from
that of Src or FAK, it is interesting to note that in all three autoinhibited
kinases, the linker segments that connect the regulatory and kinase
domains play a key role in maintaining the autoinhibited state. Addi-
tionally, in both FAK and ZAP-70, key phosphorylation sites in the
linkers are sequestered in the inactive state.Cell 129, 1177–1187, June 15, 2007 ª2007 Elsevier Inc. 1187
